Durham, North Carolina
Phase 1 cancer trials in Durham, NC
63 Phase 1 cancer studies are recruiting participants at sites in Durham as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Durham at a glance
- 63 studies are recruiting at a site in Durham.
- By phase: Phase 1 (33), Phase 1/2 (30).
- By sponsor: industry (55), university, hospital or other (8).
- By research area: Lung Cancer (17), Breast Cancer (15), Prostate Cancer (12), Lymphoma (11), Pancreatic Cancer (5), Melanoma (3).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Durham
Basic details from each study's public record (the 30 most recently updated of 63). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- Duke Cancer Institute
- Registry record
- NCT06253871 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Duke Cancer Center Durham
- Registry record
- NCT07488676 · updated
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Duke Cancer Institute
- Registry record
- NCT03424005 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Duke Cancer Institute
- Registry record
- NCT05315700 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Duke University Medical Center
- Registry record
- NCT07213791 · updated
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Duke Cancer Center
- Registry record
- NCT06120283 · updated
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Duke Cancer Center /ID# 255129
- Registry record
- NCT06084481 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Lung cancer studies recruiting in Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Duke University School of Medicine
- Registry record
- NCT05786924 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Duke University Medical Center
- Registry record
- NCT04886804 · updated
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- TRIANA Biomedicines, Inc.
- Study site
- Duke University
- Registry record
- NCT07491497 · updated
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BlossomHill Therapeutics
- Study site
- Duke Cancer Institute
- Registry record
- NCT06706076 · updated
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sairopa B.V.
- Study site
- Duke Health - Duke University Hospital
- Registry record
- NCT05856981 · updated
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Alterome Therapeutics, Inc.
- Registry record
- NCT06835569 · updated
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Study site
- Duke University
- Registry record
- NCT06179069 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Durham
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Duke University Medical Center
- Registry record
- NCT07190300 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Duke University Medical Center Duke Cancer Center
- Registry record
- NCT04221542 · updated
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Duke University Medical Center
- Registry record
- NCT06800313 · updated
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- K36 Therapeutics, Inc.
- Study site
- Duke Cancer Center
- Registry record
- NCT07103018 · updated
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Duke Univ Medical Center
- Registry record
- NCT07226986 · updated
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Duke University Medical Center
- Registry record
- NCT07206056 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- Duke University
- Registry record
- NCT05919264 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Melanoma studies recruiting in Durham
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Duke University
- Study site
- Duke University Medical Center
- Registry record
- NCT05077137 · updated
IL-17 Blockade to Decrease irAEs (REPLAY)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Duke University
- Study site
- Duke University Health System
- Registry record
- NCT07237594 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Durham, NC on ClinicalTrials.gov.
Lymphoma studies recruiting in Durham
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Duke University Medical Center
- Registry record
- NCT04726241 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- Duke University Medical Center
- Registry record
- NCT05384626 · updated
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Phase 1/2
- Ages 16 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07155226 · updated
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Phase 1/2
- From 30 days
- All sexes
- Sponsor
- Syndax Pharmaceuticals
- Study site
- Duke University Medical Center
- Registry record
- NCT04065399 · updated
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Curis, Inc.
- Study site
- Duke University Medical Center, Duke Cancer Center
- Registry record
- NCT03328078 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Durham, NC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Durham
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Duke University Medical Center - Duke Cancer Center
- Registry record
- NCT07024615 · updated
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT06885034 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Ask about studies near Durham
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections